In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Pharma Split Spur Altana Into Action?

Executive Summary

Altana AG announced in July that it would split out the pharmaceuticals division into a separately listed company sometime next year. The news followed a large acquisition in chemicals; but for pharma, the timing couldn't have been worse. Two key late-stage development projects suffered setbacks in the last 12 months, and there's little in the pipeline to replace them.
Advertisement

Related Content

European Consolidation: Serious Competition for Big Pharma?
European Consolidation: Serious Competition for Big Pharma?
Merck KGAA's Hostile Bid Catalyzes Bayer-Schering Combo
Merck KGAA's Hostile Bid Catalyzes Bayer-Schering Combo
Reviewing 2005: The Top Biopharma Stories
Pfizer Trims Altana From Pipeline
Pfizer Trims Altana From Pipeline
Serono Deals Its Way Into Oncology
Serono Deals Its Way Into Oncology
Bayer: Out of Trouble Come Opportunities

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel